Tetanus-Diphtheria-Acellular Pertussis (Tdap)

ADACEL® **Supplier: Sanofi Pasteur Limited**
BOOSTRIX® **Supplier: GlaxoSmithKline Inc.**

INDICATIONS: [A]

- Reinforcing dose in grade 9. [B]
- Pregnant people in every pregnancy, ideally provided between 27-32 weeks of gestation. [C]
- Completion of primary series in unimmunized or incompletely immunized children (7 years of age and older), adolescents and adults, including those with unknown immunization history.[D]
- Booster dose for individuals 4 years of age and older who are up-to-date for polio immunization. [E]
- Wound management (see Tetanus Prophylaxis in Wound Management). [F, G]

RECOMMENDED BY THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION BUT NOT PROVIDED FREE IN BC:

Recommended based on Good Evidence:

- All adults should receive one dose of Tdap vaccine if they have not previously received a pertussis containing vaccine in adulthood.

DOSES AND SCHEDULE: [A]

Grade 9: 1 dose given as 0.5 mL **IM** [G]

Pregnant People: 1 dose given as 0.5 mL **IM** [C]

Children and Adolescents 7-17 years of age (inclusive): [D, G]

- Booster dose for those who missed receiving the school entry booster dose:
  - 1 dose given as 0.5 mL **IM**

[A] There is no minimum interval between a dose of Td and Tdap when Tdap is being given for pertussis protection.
[B] Individuals born in 1989 or later who missed their adolescent dose of Tdap are eligible for one dose of Tdap.
[C] Tdap should be given irrespective of previous Tdap immunization history. Although recommended at 27-32 weeks of gestation, Tdap may be given from 13 weeks up to the time of delivery. For more information see Part 2 – Special Populations, People who are Pregnant or Planning a Pregnancy.
[D] Tdap-IPV is the preferred product if polio vaccine is also required, but separate Tdap and IPV may be used.
[E] Tdap is not indicated for primary immunization of children less than 7 years of age.
[F] For children 10 years of age and older who have not yet received their adolescent dose of Tdap.
[G] Children who complete their primary series or receive a booster dose of Tdap after their 10th birthday do not require an additional dose of Tdap in grade 9.

Tetanus-Diphtheria-Acellular Pertussis (Tdap)
ADACEL® Supplier: Sanofi Pasteur Limited
BOOSTRIX® Supplier: GlaxoSmithKline Inc.

DOSES AND SCHEDULE (continued):

- Incompletely immunized children and adolescents:
  - If the first dose of DTaP-containing vaccine was administered after the 1st birthday, administer additional dose(s) in order to complete a **3-dose** primary series. Given as:
    - Dose 1: 0.5 mL **IM**
    - Dose 2: 0.5 mL **IM** 4-8 weeks after 1st dose
    - Dose 3: 0.5 mL **IM** 6-12 months after 2nd dose
  - If the first dose of DTaP-containing vaccine was administered before the 1st birthday, administer additional dose(s) in order to complete a **4-dose** primary series. Given as:
    - Dose 1: 0.5 mL **IM**
    - Dose 2: 0.5 mL **IM** 4-8 weeks after 1st dose
    - Dose 3: 0.5 mL **IM** 4-8 weeks after 2nd dose
    - Dose 4: 0.5 mL **IM** 6-12 months after 3rd dose
- Unimmunized children and adolescents:
  - 3 doses given as:
    - Dose 1: 0.5 mL **IM**
    - Dose 2: 0.5 mL **IM** 4-8 weeks after 1st dose
    - Dose 3: 0.5 mL **IM** 6-12 months after 2nd dose

Adults 18 years of age and older:

- Unimmunized or incompletely immunized adults completing a 3-dose series:
  - First dose given as Tdap, followed by 2 doses of Td, given as:
    - Dose 1: 0.5 mL **IM**
    - Dose 2: 0.5 mL **IM** 4-8 weeks after 1st dose
    - Dose 3: 0.5 mL **IM** 6-12 months after 2nd dose

ADMINISTRATION:

No additional requirements.

BOOSTER DOSES:

No booster doses are recommended at this time.

SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

Tetanus-Diphtheria-acellular Pertussis (Tdap)

ADACEL® Supplier: Sanofi Pasteur Limited

BOOSTRIX® Supplier: GlaxoSmithKline Inc.

CONTRAINDICATIONS:

1. History of an anaphylactic reaction to a previous dose of tetanus, diphtheria, or pertussis-containing vaccine or to any component of the product.
2. History of Guillain-Barré Syndrome (GBS) within 8 weeks of receipt of a tetanus-containing vaccine without any other cause being identified.

PRODUCT COMPONENTS:

ADACEL®:

Potential allergens: none.

Other components: aluminum phosphate, 2-phenoxyethanol, formaldehyde, glutaraldehyde.

BOOSTRIX®:

Potential allergens: polysorbate 80.

Other components: aluminum salts, disodium phosphate, formaldehyde, glutaraldehye, glycine, monopotassium phosphate, potassium chloride.

PRECAUTIONS:

Not applicable.

SPECIAL CONSIDERATIONS:

Not applicable.

ADVERSE EVENTS:

Local: pain, redness, swelling. Local reactions may be more severe when tetanus-containing vaccines are provided after short intervals.

Systemic: fatigue, headache, fever, chills, nausea and diarrhea, muscle or joint aches.